Citius Pharmaceuticals (CTXR) investor relations material

Executive summary

• Commercial launch of LYMPHIR began in December 2025, generating $5.6 million in net revenue for the first half of fiscal 2026 with approximately 80% gross margins.

• Achieved near 100% payer coverage and advanced 83% of LYMPHIR target accounts to formulary inclusion or review.

• Expanded patient access with initial shipments to Europe and transition of patients to community infusion centers.

• Net loss increased to $28.1M for the quarter and $37.5M for the six months ended March 31, 2026, mainly due to a $19.7M contract cancellation fee and higher G&A expenses.

• Significant capital raises and a new $25M loan facility were completed post-quarter to support liquidity.

Financial highlights

• Revenue for the quarter was $1.67M and $5.61M for the six months, with gross profit margins of ~80%.

• Operating loss was $32.2M for the quarter and $41.2M for the six months, reflecting increased expenses.

• Net loss per share was $(0.95) for the quarter and $(1.34) for the six months.

• Cash and cash equivalents stood at $4.6M as of March 31, 2026.

• R&D expenses decreased to $1.6M for Q2 2026 from $3.8M in Q2 2025, reflecting reduced clinical activity.

Outlook and guidance

• Available cash resources, including recent financings, are expected to fund operations through November 2026.

• Additional capital will be required to support operations beyond this period, with ongoing capital raising initiatives.

• Completion of LYMPHIR commercial field force buildout anticipated by mid-summer to drive further market penetration.

• Management expects revenue growth as LYMPHIR gains further market acceptance and international expansion continues.

• Continued focus on advancing Mino-Lok and Halo-Lido with the FDA.